Skip to content

Interactions between genetics and diuretic medications in the kidney's clearance of uric acid

Gene-diuretic interactions in renal uric acid handling in healthy volunteers: an intervention study

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12614000871640
Enrollment
100
Registered
2014-08-14
Start date
2014-09-25
Completion date
2015-10-28
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

High blood urate levels lead to gout (the most common form of inflammatory arthritis), and may also contribute to development of heart and kidney disease. This problem is of great relevance to Aotearoa New Zealand due to the very high rates of high urate levels and severe gout in Maori and Pacific people. A number of risk factors contribute to increased urate levels in the blood. Recent research has identified a number of genes that contribute to urate levels. Diuretic medications, frequently used to treat high blood pressure and heart failure, also increase blood urate levels. This short-term intervention study will examine the way that genes and diuretic medications interact to influence the person’s ability to clear urate from the body. Understanding these interactions may, in time, allow individualized treatment decisions; for example, the presence of certain gout risk genes may guide selection of therapies for heart failure and hypertension.

Interventions

Single dose of oral frusemide 40mg

Sponsors

University of Auckland
Lead SponsorUniversity

Study design

Allocation
Non-randomised trial
Primary purpose
Prevention

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

a. Age from 18 to 50 years b. Able to provide written informed consent c. eGFR>60

Exclusion criteria

a. History of gout b. History of diabetes c. Fasting capillary glucose >6mmol/L d. Existing diuretic use e. Hypokalaemia (serum potassium <3.5mmol/L) f. Recurrent episodes of vasovagal syncope or fainting g. Previous intolerance to frusemide

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 27, 2026